Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Mar 15:272:117082.
doi: 10.1016/j.bios.2024.117082. Epub 2024 Dec 25.

Effect of electrochemical topology on detection sensitivity in MEA assay for drug-induced cardiotoxicity screening

Affiliations

Effect of electrochemical topology on detection sensitivity in MEA assay for drug-induced cardiotoxicity screening

Byunggik Kim et al. Biosens Bioelectron. .

Abstract

Cardiotoxicity remains a major challenge in drug development, accounting for 45% of medication withdrawals due to cardiac ischemia and arrhythmogenicity. To overcome the limitations of traditional multielectrode array (MEA)-based cardiotoxicity assays, we developed a Nafion-coated NanoMEA platform with decoupled reference electrodes, offering enhanced sensitivity for electrophysiological measurements. The 'Decoupled' configuration significantly reduced polarization resistance (Rp) from 12.77 MΩ to 3.41 MΩ, improving charge transfer efficiency as demonstrated by electrochemical impedance spectroscopy and cyclic voltammetry. Additionally, the limit of detection significantly decreased from 0.175 MΩ (Coupled) to 0.040 MΩ (Decoupled), underscoring the system's enhanced sensitivity. Using human-induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs), we evaluated the effects of three proarrhythmic drugs: Ranolazine, Domperidone, and Sotalol. Under the decoupled condition, the platform exhibited reductions in IC50 values for Domperidone (0.71 μM-0.29 μM), Sotalol (7.61 μM-0.27 μM), and Ranolazine (53.08 μM-5.89 μM), demonstrating significantly improved drug detection sensitivity. Longitudinal analysis revealed significant alterations in key electrophysiological parameters, including beating period (BP), field potential duration (FPD), spike slope, and amplitude, which were consistent with the known pharmacological actions of these drugs. Further validation through action potential (AP) waveform analysis showed enhanced repolarization dynamics, confirming the platform's predictive capabilities. Our findings highlight the critical role of electrochemical topology in optimizing MEA performance. The NanoMEA system, featuring decoupled Nafion-coated electrodes, represents a robust and sensitive platform for cardiotoxicity screening, setting a new standard for preclinical drug safety assessment and advancing bioelectronic device design for cardiac research.

Keywords: Cardiotoxicity screening; Electrochemical topology; Human iPSC-derived cardiomyocytes; Impedance spectroscopy; Microelectrode array (MEA); NanoMEA platform.

PubMed Disclaimer

Conflict of interest statement

Declaration of competing interest Deok-Ho Kim is a co-founder and scientific advisory board member at Curi Bio, Inc. Todd. J. Herron is a consultant and scientific advisory board member at StemBioSys, Inc.

References

    1. Antzelevitch C., et al. (2011). "Electrophysiologic basis for the antiarrhythmic actions of ranolazine." Heart Rhythm 8(8): 1281–1290. - PMC - PubMed
    1. Arita M., et al. (1976). "Automaticity and time-dependent conduction disturbance produced in canine ventricular myocardium. New aspects for initiation of ventricular arrhythmias." Jpn Circ J 40(12): 1409–1418. - PubMed
    1. Blinova K., et al. (2018). "International Multisite Study of Human-Induced Pluripotent Stem Cell-Derived Cardiomyocytes for Drug Proarrhythmic Potential Assessment." Cell Rep 24(13): 3582–3592. - PMC - PubMed
    1. Campbell K., et al. (2012). "Spatial gradients in action potential duration created by regional magnetofection of hERG are a substrate for wavebreak and turbulent propagation in cardiomyocyte monolayers." J Physiol 590(24): 6363–6379. - PMC - PubMed
    1. Cardinale D., et al. (2020). "Cardiotoxicity of Anthracyclines." Front Cardiovasc Med 7: 26. - PMC - PubMed

LinkOut - more resources